US 12,312,345 B2
Fluoroalkyl-oxadiazoles and uses thereof
Snahel Patel, South San Francisco, CA (US); Mohammad A. Mandegar, South San Francisco, CA (US); Pingyu Ding, South San Francisco, CA (US); Ulhas Bhatt, South San Francisco, CA (US); Martin Holan, South San Francisco, CA (US); John Lee, South San Francisco, CA (US); Yihong Li, South San Francisco, CA (US); Julio Medina, South San Francisco, CA (US); Alok Nerurkar, South San Francisco, CA (US); Frederick Seidl, South San Francisco, CA (US); David Sperandio, South San Francisco, CA (US); and Tien Widjaja, South San Francisco, CA (US)
Assigned to Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed by Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed on Dec. 1, 2023, as Appl. No. 18/526,922.
Application 18/526,922 is a continuation of application No. 18/087,933, filed on Dec. 23, 2022, granted, now 11,926,622.
Application 18/087,933 is a continuation of application No. 17/731,949, filed on Apr. 28, 2022, granted, now 11,578,066, issued on Feb. 14, 2023.
Application 17/731,949 is a continuation of application No. PCT/US2020/066439, filed on Dec. 21, 2020.
Claims priority of provisional application 63/064,516, filed on Aug. 12, 2020.
Claims priority of provisional application 63/027,602, filed on May 20, 2020.
Claims priority of provisional application 62/951,853, filed on Dec. 20, 2019.
Prior Publication US 2024/0182462 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01) 32 Claims
 
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
R1 is selected from the group consisting of:

OG Complex Work Unit Chemistry
Ra is selected from the group consisting of H, halo, C1-3 alkyl, cycloalkyl, haloalkyl, and alkoxy;
R2 and R3 are independently selected from the group consisting of H, halogen, alkoxy, haloalkyl, aryl, heteroaryl, alkyl, and cycloalkyl, or R2 and R3 together with the atom to which they are attached form a cycloalkyl or heterocyclyl;
R4 is alkylenealkoxy, alkyleneheterocyclyl, —S(O)2alkyl, —S(O)2cycloalkyl, —S(O)2alkylenecycloalkyl, —S(O)2alkyleneheterocyclyl, —S(O)2N(H)alkyleneheterocyclyl, —C(O)alkyl, —C(O)cycloalkyl, —C(O)alkylenecycloalkyl, —C(O)alkyleneheterocyclyl, or —C(O)N(H)alkyleneheterocyclyl, each of which is optionally substituted with one or more oxo, halogen, C1-5 alkyl, C1-5 haloalkyl, C1-5 alkoxy, C1-5 haloalkoxy, C3-12 cycloalkyl, cyano, and amido;
R5 is alkyl, haloalkyl, alkylene-aryl, heterocyclyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted with one or more oxo, halogen, C1-5 alkyl, C1-5 haloalkyl, C1-5 alkoxy, C1-5 haloalkoxy, C3-12 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 14-membered heteroaryl, ester, amido, cyano, C1-5 cyanoalkyl, and C1-5 alkylamino;
or R4 and R5 together with the atom to which they are attached form a heterocyclyl, each of which is optionally substituted with one or more oxo, halogen, C1-5 alkyl, C1-5 haloalkyl, C1-5 alkoxy, C1-5 haloalkoxy, cyano, C3-12 cycloalkyl, 3- to 12-membered heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, and 5- to 14-membered heteroaryl;
X1 is selected from the group consisting of S, O, NH and NR6, wherein R6 is selected from the group consisting of C1-C6 alkyl, alkoxy, haloalkyl, cycloalkyl, and heterocyclyl;
Y is N; and
n is selected from 0, 1, and 2.